Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (GB:0JDI)
LSE:0JDI
Holding GB:0JDI?
Track your performance easily
0JDI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.40 - $53.95
Previous Close$39.11
Volume703.00
Average Volume (3M)520.00
Market Cap
$6.07B
Enterprise Value$4.20B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$210.86M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Oct 31, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding146,211,091
10 Day Avg. Volume392
30 Day Avg. Volume520
Standard Deviation0.10
R-Squared0.01
Alpha-0.00169
Financial Highlights & Ratios
Price to Book (P/B)21.62
Price to Sales (P/S)6.92
Price to Cash Flow (P/CF)-11.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.17
Enterprise Value/Gross Profit5.40
Enterprise Value/Ebitda-15.27
Forecast
1Y Price Target
$61.82Price Target Upside58.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue of $225mm beat consensus estimates, primarily driven by R&D revenue.
Market PositioningThe cardiomyopathy market is expected to be massive, supporting the sales forecast for TTR-silencers.
Product DevelopmentIONS noted the raise has strengthened the company’s balance sheet ahead of new product launches and upcoming Ph3 readouts.
Bears Say
Clinical Trials And EfficacyIONS announced discontinuation of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) as both assets demonstrated insufficient efficacy to advance into Phase 3.
Drug Development And PipelineIONS has advanced too many promising drugs that inevitably reduce focus, consume resources, and increase ambiguity around the size/fate of each opportunity.
Financial PerformanceUpdating the model for the offering reduces the price target from $62 to $56.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.76% Insiders
36.26% Mutual Funds
0.24% Other Institutional Investors
48.12% Public Companies and
Individual Investors
0JDI FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest share price was $36.40 and its highest was $53.95 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 12 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.925 by $0.475.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -$1.12.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 157,711,090 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.925. Following the earnings report the stock price went up 2.207%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 165M.
---
Ionis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.82 (58.07% Upside)
$61.82 (58.07% Upside)
Blogger Sentiment
Bullish
GB:0JDI Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.70%
12-Months-Change
Fundamentals
Return on Equity
-105.63%
Trailing 12-Months
Asset Growth
-9.42%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
0JDI Company Deck
---
0JDI Earnings Call
Q2 2024
0:00 / 0:00
---
0JDI Revenue Breakdown
60.82% R&D
39.18% Commercial
---
0JDI Stock 12 Month Forecast
Average Price Target
$61.82
▲(58.07% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
AnaptysBio
―
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Best Analysts Covering 0JDI
1 Year
1 Year Success Rate
17/27 ratings generated profit
1 Year Average Return
+8.51%
reiterated a buy rating 3 months ago
Copying David Lebowitz's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +8.51% per trade.
---